COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00403988
Recruitment Status : Terminated (The results of a same study design have shown low response with important side effects. Accordingly & ethicly, the study has been stopped.)
First Posted : November 27, 2006
Last Update Posted : November 4, 2008
Information provided by:
American University of Beirut Medical Center

Brief Summary:

Study Objective :

To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer

Condition or disease Intervention/treatment Phase
Breast Neoplasms Drug: Oxaliplatin Drug: vinorelbine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
Study Start Date : June 2004
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. overall response rate [ Time Frame: During the Study Conduct ]
  2. time to progression (TTP). [ Time Frame: during the study conduct ]

Secondary Outcome Measures :
  1. survival [ Time Frame: During the study conduct ]
  2. tolerance [ Time Frame: During the study conduct ]
  3. toxicity. [ Time Frame: During the study conduct ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic, histologically or cytologically proven breast cancer.
  • At least one bi-dimensionally measurable lesion.
  • Previous treatment with chemotherapy as first line for metastatic disease is mandatory especially with anthracyclines +/- the Taxanes.
  • Treatment as adjuvant is allowed.
  • World Health Organization-ECOG performance status 0-2.
  • Adequate renal function (Creatinine <= 1.4 or Creatinine clearance >= 30 ml/min)
  • Adequate hepatic function (Liver Function Tests not more than 3 times the normal values)
  • Adequate bone marrow reserve is required (Neutrophils (PMN) >= 2000/mm2 and Platelets >= 100,000/mm2)
  • Patient who will receive Herceptin should have an over-expression of HER2-neu.

Exclusion Criteria:

  • Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria grade more than one).
  • Pregnant or breast-feeding.
  • History of prior malignancies (with the exception of excised cervical carcinoma-in-situ or non-melanoma cell skin carcinoma).
  • Receiving or had received, any treatment with experimental drugs.
  • Had known brain or leptomeningeal involvement.
  • Had a serious medical condition like congestive heart failure or an Ejection Fraction ≥ 40 %.
  • The presence of bone as a sole site of metastasis.
  • Radiation therapy to all areas of measurable disease less than four weeks before treatment.
  • Creatinine two times above the normal range
  • Hypercalcemia
  • Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion - Ascites - Pericardial effusion.
  • Concomitant steroid intake for > 4 weeks
  • Bilirubin two times above the normal range

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00403988

Layout table for location information
Beirut, Lebanon
Sponsors and Collaborators
American University of Beirut Medical Center
Layout table for additonal information Identifier: NCT00403988    
Other Study ID Numbers: L_9116
First Posted: November 27, 2006    Key Record Dates
Last Update Posted: November 4, 2008
Last Verified: August 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action